Heron Therapeutics, Inc. (HRTX)

2,8400 +0,2300 (+8,81%) Börsenschluss: 04:00PM EDT

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400
https://www.herontx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 126

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Craig Alexander Collard	CEO & Director	5,49k	N/A	1966
Ms. Ira Duarte	Executive VP & CFO	636,89k	N/A	1969
Dr. William P. Forbes Pharm. D., Pharm.D.	Executive VP & Chief Development Officer	734,62k	N/A	1962
Mr. Ryan Craig	Vice President of Marketing	N/A	N/A	N/A
Mr. Sean T. Ristine	Senior Vice President of Human Resources	N/A	N/A	1970
Mr. Robert Sullivan	Senior VP of Oncology Care Franchise & Commercial Operations	N/A	N/A	1978
Jeff Cohn	Executive Director, Assistant General Counsel & Assistant Secretary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Corporate Governance

Heron Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 2. Die grundlegenden Scores sind Audit: 8, Vorstand: 4, Shareholderrechte: 1, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.